Eric Nadler

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management.

Martin J. Heslin, J J Lewis, Eric Nadler et al. · Journal of Clinical Oncology · 1997 · 316 citations · Full text

Medicine, Oncology, Surgery +9

Do Oncologists Believe New Cancer Drugs Offer Good Value?

Eric Nadler, Ben Eckert, Peter J. Neumann · The Oncologist · 2006 · 185 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +14

Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists

Peter J. Neumann, Jennifer A. Palmer, Eric Nadler et al. · Health Affairs · 2010 · 142 citations

Pharmacy, Oncology, Pharmacoeconomics +16

Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs

Scott R. Berry, Chaim M. Bell, Peter A. Ubel et al. · Journal of Clinical Oncology · 2010 · 77 citations · Full text

Public Affairs, Health Policy, Oncology +17